Article
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Biochemical and biophysical research communications - 1 Jan 2018
Tamura Tomoki, Kato Yuka, Ohashi Kadoaki, Ninomiya Kiichiro, Makimoto Go, Gotoda Hiroko, Kubo Toshio, Ichihara Eiki, Tanaka Takehiro, Ichimura Koichi, Maeda Yoshinobu, Hotta Katsuyuki, Kiura Katsuyuki
Abstract excerpt
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a key therapy used for patients with EGFR-mutant non-small cell lung cancer (NSCLC), some of whom do not respond well to its therapy. Cytokine including IL-6 secreted by tumour cells is postulated as a potential mechanism for the primary resistance or low sensitivity to EGFR-TKIs. Fifty-two patients with advanced EGFR-mutant...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Female
- Gefitinib
- Genetic Predisposition to Disease